Mezigdomide
- Generic Name
- Mezigdomide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H30FN5O4
- CAS Number
- 2259648-80-9
- Unique Ingredient Identifier
- LA88IH4O02
- Background
Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma).
- Associated Conditions
- -
- Associated Therapies
- -
Mezigdomide and Elranatamab for Relapsed And/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-10-17
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- YOUNGIL KOH
- Target Recruit Count
- 75
- Registration Number
- NCT06645678
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT06627751
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT06318676
- Locations
- 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸PANAX, Miami Lakes, Florida, United States
🇺🇸Omega Research Group - Orlando, Orlando, Florida, United States
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Celgene
- Target Recruit Count
- 156
- Registration Number
- NCT06163898
- Locations
- 🇺🇸
Local Institution - 0035, New Haven, Connecticut, United States
🇺🇸Local Institution - 0018, New York, New York, United States
🇺🇸Local Institution - 0033, Birmingham, Alabama, United States
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 111
- Registration Number
- NCT06121843
- Locations
- 🇺🇸
University Of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Local Institution - 0002, Phoenix, Arizona, United States
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kathleen Dorritie
- Target Recruit Count
- 34
- Registration Number
- NCT06050512
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT05707390
- Locations
- 🇺🇸
Orlando Clinical Research Center OCRC, Orlando, Florida, United States
🇺🇸The Texas Liver Institute, San Antonio, Texas, United States
🇺🇸PANAX, Miami Lakes, Florida, United States
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
- Conditions
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 525
- Registration Number
- NCT05552976
- Locations
- 🇺🇸
USA Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸TOI Clinical Research, Cerritos, California, United States
🇺🇸Kaiser Permanente - Irvine, Irvine, California, United States
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 810
- Registration Number
- NCT05519085
- Locations
- 🇺🇸
Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 300
- Registration Number
- NCT02343042
- Locations
- 🇺🇸
Sarah Cannon-Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.